Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure Association and the Cardio‐Oncology Council of the European Society of Cardiology

2020 | journal article. A publication with affiliation to the University of Göttingen.

Jump to: Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​Pudil, Radek, et al. "Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure Association and the Cardio‐Oncology Council of the European Society of Cardiology​." ​European Journal of Heart Failure, vol. 22, no. 11, ​2020, pp. 1966​-1983​, ​doi: 10.1002/ejhf.2017. 

Documents & Media

License

GRO License GRO License

Details

Authors
Pudil, Radek; Mueller, Christian ; Čelutkienė, Jelena; Henriksen, Peter A.; Lenihan, Dan; Dent, Susan; Barac, Ana; Stanway, Susanna; Moslehi, Javid; Suter, Thomas M.; Ky, Bonnie; Štěrba, Martin; Cardinale, Daniela; Cohen‐Solal, Alain; Tocchetti, Carlo Gabriele; Farmakis, Dimitrios; Bergler‐Klein, Jutta; Anker, Markus S.; Von Haehling, Stephan ; Belenkov, Yury; Iakobishvili, Zaza; Maack, Christoph; Ciardiello, Fortunato; Ruschitzka, Frank; Coats, Andrew J.S.; Seferovic, Petar; Lainscak, Mitja; Piepoli, Massimo F.; Chioncel, Ovidiu; Bax, Jereon; Hulot, Jean‐Sebastien; Skouri, Hadi; Hägler‐Laube, Eva Simona; Asteggiano, Riccardo; Fernandez, Teresa Lopez; Boer, Rudolf A.; Lyon, Alexander R.
Issue Date
2020
Journal
European Journal of Heart Failure 
ISSN
1388-9842
eISSN
1879-0844
Language
English

Reference

Citations


Social Media